Trexquant Investment LP Sells 293,781 Shares of Guardant Health, Inc. $GH

Key Points

• Trexquant Investment LP significantly decreased its stake in Guardant Health, Inc. by 62.0%, owning 180,390 shares valued at approximately $7,685,000 after selling 293,781 shares in the first quarter.
• Several institutional investors have increased their holdings; for example, Invesco Ltd. raised its position by 100.9%, acquiring over 1.4 million additional shares.
• Analyst ratings for Guardant Health have generally improved, with most firms raising price targets and giving the stock a consensus rating of "Buy" and a price target of $57.50.

Trexquant Investment LP reduced its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 62.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 180,390 shares of the company's stock after selling 293,781 shares during the period. Trexquant Investment LP owned 0.15% of Guardant Health worth $7,685,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also made changes to their positions in GH. SVB Wealth LLC acquired a new position in Guardant Health in the 1st quarter valued at approximately $54,000. NewEdge Advisors LLC boosted its holdings in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after purchasing an additional 230 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Guardant Health in the 4th quarter valued at $61,000. GF Fund Management CO. LTD. acquired a new position in shares of Guardant Health in the 4th quarter valued at $79,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Guardant Health during the 1st quarter worth about $97,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on GH shares. BTIG Research increased their price objective on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday. Scotiabank lifted their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a research note on Thursday, July 31st. Evercore ISI raised shares of Guardant Health to a "strong-buy" rating in a research note on Monday, July 14th. Raymond James Financial increased their price objective on shares of Guardant Health from $59.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, July 31st. Finally, Mizuho lifted their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the company an "outperform" rating in a report on Friday, June 13th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $58.24.

Guardant Health Stock Performance

GH stock traded down $4.72 on Thursday, reaching $60.34. The company had a trading volume of 3,346,443 shares, compared to its average volume of 2,380,735. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $68.00. The company's fifty day moving average is $52.71 and its 200 day moving average is $47.02. The company has a market cap of $7.52 billion, a P/E ratio of -18.01 and a beta of 1.46.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.08. The business had revenue of $232.09 million for the quarter, compared to analysts' expectations of $211.19 million. The company's revenue for the quarter was up 31.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.84) EPS. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Activity at Guardant Health

In other Guardant Health news, Director Ian T. Clark sold 6,672 shares of Guardant Health stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total value of $322,791.36. Following the completion of the transaction, the director directly owned 9,851 shares in the company, valued at $476,591.38. The trade was a 40.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Myrtle S. Potter sold 2,626 shares of Guardant Health stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $49.70, for a total value of $130,512.20. Following the sale, the director directly owned 18,180 shares in the company, valued at approximately $903,546. This trade represents a 12.62% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 233,862 shares of company stock valued at $11,770,909. 6.10% of the stock is currently owned by insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.